Literature DB >> 1690209

Biological agents in cancer therapy: cytokines, monoclonal antibodies and vaccines.

H F Oettgen1.   

Abstract

Biological approaches to cancer therapy have gone through phases of early excitement and subsequent neglect and ridicule, and have now entered an era of renewed interest. Unlike Coley and his contemporaries a century ago we are using highly purified agents of impressive potency and specificity of action in our current studies. We have come a long way in dissecting their interactions in inflammation, immunity and hematopoiesis, but we have a long way to go in defining optimal conditions for their use in therapy. However one judges the promise biological agents hold for cancer therapy, it seems certain that they will be prominent subjects of future research.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690209     DOI: 10.1007/bf01612653

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  8 in total

1.  The role of the reticuloendothelial system in the host reaction to neoplasia.

Authors:  L J OLD; B BENACERRAF; D A CLARKE; E A CARSWELL; E STOCKERT
Journal:  Cancer Res       Date:  1961-10       Impact factor: 12.701

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

3.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

Authors:  S Vadhan-Raj; C Cordon-Cardo; E Carswell; D Mintzer; L Dantis; C Duteau; M A Templeton; H F Oettgen; L J Old; A N Houghton
Journal:  J Clin Oncol       Date:  1988-10       Impact factor: 44.544

5.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

6.  Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

Authors:  J L Gabrilove; A Jakubowski; H Scher; C Sternberg; G Wong; J Grous; A Yagoda; K Fain; M A Moore; B Clarkson; Herbert F Oettgen; Kirby Alton; Karl Welte; Lawrence Souza
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

Authors:  C M Pinsky; F J Camacho; D Kerr; N L Geller; F A Klein; H A Herr; W F Whitmore; H F Oettgen
Journal:  Cancer Treat Rep       Date:  1985-01
  8 in total
  1 in total

1.  Dr William Coley and tumour regression: a place in history or in the future.

Authors:  S A Hoption Cann; J P van Netten; C van Netten
Journal:  Postgrad Med J       Date:  2003-12       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.